A new meta-analysis questions the long-held belief that an invasive strategy for patients with non–ST-segment elevation myocardial infarction (NSTEMI) always provides superior outcomes. Published in JACC: Advances, the investigation found no significant difference in overall or cardiac-related mortality between routine invasive strategies such as coronary angiography with potential revascularization and conservative, medication-based management in older adults. “Routine invasive strategy was not superior to conservative management in elderly patients with NSTEMI in all-cause mortality (odds ratio [OR]: 1.07; 95% confidence interval [CI]: 0.90-1.26; P= 0.44; I²: 0%) and cardiac-related death (OR: 1.05; 95% CI: 0.86-1.29; P = 0.64; I²: 0%),” wrote the authors of the paper, led by Abiodun Idowu, MD, from Jefferson Einstein Philadelphia Hospital in Pennsylvania. “Routine invasive strategy, however, confers significant benefits in reducing the risk of myocardial reinfarction (OR: 0.71; 95% CI: 0.58-0.86; P = 0.0005; I²: 34%) and urgent revascularization (OR: 0.31; 95% CI: 0.23-0.42; P < 0.00001; I²: 0%).” The strategy did not predispose NSTEMI patients aged ≥70 years to increased susceptibility to cerebrovascular accident (OR: 1.13; 95% CI: 0.82-1.55; P = 0.45; I²: 0%). Life expectancy Further findings clarified that while invasive management can reduce repeat heart attacks and emergency interventions, it did not necessarily extend life expectancy in this population. “From a mortality perspective, conservative management may be as effective as routine invasive strategies in patients aged over 70 years with NSTEMI,” the paper’s authors concluded. The differences in treatment timing and completeness of revascularization may explain why prior observational studies showed stronger benefits for invasive therapy. Notably, the meta-analysis also found a higher risk of bleeding complications among those receiving invasive treatment with more patients experiencing major bleeding events in the routine invasive group (6.8%) compared to 4.9% in the conservative strategy arm (OR: 1.43; 95% CI: 1.04-1.95; P = 0.03). Current European and American guidelines already advocate for individualized treatment decisions in older adults, balancing potential benefits with risks such as bleeding or procedural complications. The authors called for further research to explore whether complete revascularization strategies could improve survival without increasing harm. Treatment options In an accompanying editorial, Abdulla A. Damluji, MD, PhD, from Cleveland Clinic in Ohio, Naila Ijaz, MD, from Thomas Jefferson University Hospital in Philadelphia, and Michael G. Nanna, MD, from Yale School of Medicine in New Haven, Connecticut, reflected on the complexity of treating older adults with NSTEMI using current treatment options. “One path includes invasive cardiovascular care for management of acute coronary syndrome (ACS), which may prevent future myocardial infarctions and urgent revascularization, but it can lead to major bleeding events,” the editorialists wrote. They added that the other path included a conservative approach that avoided procedure-related adverse events, but it increased the risk of future ischemic events later in life. The commentators noted that “the care of the older adult is nuanced and cannot be reduced to chronological age alone.” Instead, they called for patient-centered, multidisciplinary care that considered frailty, cognition and personal goals when deciding whether to pursue invasive or conservative management. Source: Routine Invasive vs Conservative Management of NSTEMI in Elderly Patients: Updated Meta-Analysis of Randomized Trials. JACC: Advances, 2025. (Article in Press). Damluji AA, Ijaz N, Nanna MG. Older Adults With NSTEMI: Picking the Patient’s Future. J Am Coll Cardiol Adv. 2025. (Article in Press). Image Credit: interstid – stock.adobe.com